What is Spinogenix?
Spinogenix operates as a clinical-stage biopharmaceutical entity dedicated to the development of novel small-molecule therapies. The company's core mission is to address the root causes of neurological, psychiatric, and neurodevelopmental disorders by repairing synaptic connections within the brain. Unlike conventional treatments that focus on palliative symptom control, Spinogenix utilizes a proprietary platform to enhance neuronal function, aiming to restore cognitive, behavioral, and motor capabilities. This focus on synaptic plasticity places the company at the forefront of neuro-regenerative medicine, offering a transformative potential for patients suffering from complex brain health conditions.
How much funding has Spinogenix raised?
Spinogenix has raised a total of $10.6M across 1 funding round:
Stock/Share Issuance
$10.6M
Stock/Share Issuance (2026): $10.6M, investors not publicly disclosed
Key Investors in Spinogenix
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Spinogenix?
With this major strategic investment, Spinogenix is well-positioned to accelerate its clinical development pipeline and scale its research operations. The influx of capital will likely be directed toward advancing its lead investigational candidates through rigorous human trials, further validating its synaptic repair platform. As the company transitions into more advanced clinical phases, the focus will shift toward regulatory milestones and potential commercialization strategies. Investors and industry stakeholders will be closely monitoring the firm's ability to translate its preclinical success into tangible therapeutic outcomes, which could redefine the standard of care for neurodegenerative diseases globally.
See full Spinogenix company page
